We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Gene Fusion Protein Proposed as Prostate Cancer Biomarker

By LabMedica International staff writers
Posted on 14 Oct 2019
Print article
Image: Human Kallikrein 4 (KLK4) protein complexed with nickel and p-aminobenzamidine  (Photo courtesy of Wikimedia Commons).
Image: Human Kallikrein 4 (KLK4) protein complexed with nickel and p-aminobenzamidine (Photo courtesy of Wikimedia Commons).
A novel gene fusion product has been proposed as a biomarker for the non-invasive diagnosis of prostate cancer.

Investigators at the Henry Ford Health System (Detroit, MI, USA) recently presented the functional characterization of pseudogene-associated recurrent gene fusion in prostate cancer. The fusion gene KLK4-KLKP1 was formed by the fusion of the protein-coding gene KLK4 (Kallikrein 4) with the noncoding pseudogene KLKP1.

Pseudogenes are segments of DNA that are related to real genes. Pseudogenes have lost at least some functionality, relative to the complete gene, in cellular gene expression or protein-coding ability. Pseudogenes often result from the accumulation of multiple mutations within a gene whose product is not required for the survival of the organism, but can also be caused by genomic copy number variation (CNV). Although not fully operational, pseudogenes may be functional, similar to other kinds of noncoding DNA, which can perform regulatory tasks.

Currently, diagnostic tests for prostate cancer are not sufficiently specific to be able to differentiate individuals without prostate cancer, those with low risk disease that is unlikely to be of clinical significance, and those with disease that should be treated. To rectify this situation, the investigators carried out a study that began with the screening of a cohort of 659 patients (380 Caucasian American; 250 African American, and 29 patients from other races).

Results of the screen revealed that the KLK4-KLKP1 gene fusion product was expressed in about 32% of prostate cancer patients. Furthermore, screening of patient urine samples showed that KLK4-KLKP1 could be detected non-invasively in urine.

Development of an antibody specific to the KLK4-KLKP1 fusion protein confirmed the expression of the full-length KLK4-KLKP1 protein in prostate tissues. In vitro and in vivo functional assays to study the oncogenic properties of KLK4-KLKP1 confirmed its role in cell proliferation, cell invasion, intravasation, and tumor formation.

"The unique feature of this fusion gene is the conversion of the noncoding pseudogene KLKP1 into a protein coding gene, and its unique expression in about 30% of high Gleason grade prostate cancer," said senior author Dr. Nallasivam Palanisamy, associate scientist in cancer research at the Henry Ford Health System. "Like other ETS family gene fusions, KLK4-KLKP1 can also be detected in the urine samples of patients with prostate cancer, enabling non-invasive detection of prostate cancer. Given the unique feature of this fusion, prostate cancer specific expression, oncogenic properties, and noninvasive detection, this novel gene fusion has the potential to be used as a biomarker for early detection of prostate cancer and a therapeutic target."

The gene fusion paper was published in the October 2019 issue of the journal Neoplasia.

Related Links:
Henry Ford Health System

Gold Supplier
COVID-19 Real Time RT-PCR Kit
respiraScreen 1
New
Integrated Urinalysis Chemistry Analyzer
AVE-772
New
Automatic Urine Sediment Analyzer
US-120
New
5-Part Differential Hematology Analyzer
Abacus 5

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: The SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian is used to generate strand-specific RNA-seq libraries (Photo courtesy of Takara Bio)

Cell-free RNA Profiles Gauge Preeclampsia Risk Months Before Symptoms

The period from conception to delivery represents the most rapid growth and development in an individual’s life. The ability to support this development requires dramatic and inadequately understood alterations... Read more

Hematology

view channel
Image: QX200 AutoDG ddPCR System and QXDx BCR-ABL %IS Kit (Photo courtesy of Bio-Rad)

ddPCR Developed for BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia

Droplet digital polymerase chain reaction (ddPCR) is a novel polymerase chain reaction (PCR) technique reliant on massive sample partitioning to generate individual reaction chambers (droplets) in which... Read more

Industry

view channel
Illustration

Global Coagulation Analyzers Market Driven by Growing Awareness About Timely Diagnosis of Blood Clots

The global coagulation analyzers market is expected to reach USD 11.7 billion by 2028, driven by the increasing understanding of blood clots and the fact that they can be avoided with early detection.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.